Syndax Pharmaceuticals, Inc. (SNDX)
9.54
+0.17
(+1.81%)
USD |
NASDAQ |
Nov 06, 16:00
9.79
+0.25
(+2.62%)
After-Hours: 20:00
Syndax Pharmaceuticals Cash from Operations (Quarterly) : -27.25M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -27.25M |
| June 30, 2026 | -30.27M |
| March 31, 2026 | -50.34M |
| December 31, 2025 | -69.49M |
| September 30, 2025 | -70.54M |
| June 30, 2025 | -87.80M |
| March 31, 2025 | -95.16M |
| December 31, 2024 | -57.39M |
| September 30, 2024 | -62.32M |
| June 30, 2024 | -71.64M |
| March 31, 2024 | -83.55M |
| December 31, 2023 | -41.35M |
| September 30, 2023 | -44.65M |
| June 30, 2023 | -35.37M |
| March 31, 2023 | -39.23M |
| December 31, 2022 | -22.89M |
| September 30, 2022 | -28.54M |
| June 30, 2022 | -40.31M |
| March 31, 2022 | -41.93M |
| December 31, 2021 | 100.71M |
| September 30, 2021 | -24.94M |
| June 30, 2021 | -24.04M |
| March 31, 2021 | -22.59M |
| December 31, 2020 | -15.63M |
| September 30, 2020 | -18.30M |
| Date | Value |
|---|---|
| June 30, 2020 | -21.41M |
| March 31, 2020 | -15.92M |
| December 31, 2019 | -12.73M |
| September 30, 2019 | -8.529M |
| June 30, 2019 | -12.52M |
| March 31, 2019 | -16.83M |
| December 31, 2018 | -15.04M |
| September 30, 2018 | -18.47M |
| June 30, 2018 | -15.15M |
| March 31, 2018 | -19.87M |
| December 31, 2017 | -12.72M |
| September 30, 2017 | -10.18M |
| June 30, 2017 | -11.80M |
| March 31, 2017 | -12.67M |
| December 31, 2016 | -10.42M |
| September 30, 2016 | -11.45M |
| June 30, 2016 | -6.89M |
| March 31, 2016 | -6.403M |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | -2.602M |
| June 30, 2014 | -3.804M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | -- |
| Emergent BioSolutions, Inc. | 100.10M |
| Incyte Corp. | -675.32M |
| Vertex Pharmaceuticals, Inc. | 643.10M |
| Travere Therapeutics, Inc. | 98.20M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -176.47M |
| Cash from Financing (Quarterly) | 3.189M |
| Free Cash Flow | -177.46M |
| Free Cash Flow Per Share (Quarterly) | -0.3035 |
| Free Cash Flow to Equity (Quarterly) | -27.29M |
| Free Cash Flow to Firm (Quarterly) | -14.28M |
| Free Cash Flow Yield | -20.99% |